TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92581

Peptide_Name

R-Lycosin I derivative 8a

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 23-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

N-terminal: 3′-Aminopropyl-D-glucopyranoside

Sequence

RGWFRAMRSIARFIARERLRGHL

FASTA

>TPDB92581|Anticancer|length=23
RGWFRAMRSIARFIARERLRGHL

Formula C127H207N47O27S1

Absent Amino Acids NDCQKPTYV

Common Amino Acids R

Mass 2856.40

PI 12.80

Basic Residues 8

Acidic Residues 1

Hydrophobic Residues 11

Net Charge +6

Boman Index 2.21

Hydrophobicity -0.487

Aliphatic Index 80.87

Half Life

Mammalian: 1 hour Yeast: 2 min E.coli: 2 min

Extinction Coefficient Cystines 5500

Absorbance 280nm 192.55

Polar Residues 1

number

3

A

7

R

0

N

0

D

0

C

1

E

0

Q

2

G

1

H

2

I

2

L

0

K

1

M

2

F

0

P

1

S

0

T

1

W

0

Y

0

V

Amino Acid Distribution

A: 3 R: 7 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 2 H: 1 I: 2 L: 2 K: 0 M: 1 F: 2 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 0

Length

23

Formula

C127H207N47O27S1

Mass

2856.40

PI

12.80

Net Charge

+6

Boman Index

2.21

Hydrophobicity

-0.487

C_terminal_Modification

Free

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

3′-Aminopropyl-D-glucopyranoside

Nature

Anticancer

Origin

Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 10.1 ± 0.2 µM

Detail Source Activity Anticancer

Activity Measurement 10.1

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay CCK-8 assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 9.6 ± 0.3 µM

Detail Source Activity Anticancer

Activity Measurement 9.6

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay CCK-8 assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 8.5 ± 0.4 µM

Detail Source Activity Anticancer

Activity Measurement 8.5

Target

Cancer Type Lung Cancer

Cell Line H-460

Tissue Affected Lung

Assay & Model

Assay CCK-8 assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 13.0 ± 0.2 µM

Detail Source Activity Anticancer

Activity Measurement 13.0

Target

Cancer Type Lung Cancer

Cell Line H-1437

Tissue Affected Lung

Assay & Model

Assay CCK-8 assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 12.6 ± 0.6 µM

Detail Source Activity Anticancer

Activity Measurement 12.6

Target

Cancer Type Gastric Cancer

Cell Line HGC-27

Tissue Affected Not Available

Assay & Model

Assay CCK-8 assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 6.9 ± 0.4 µM

Detail Source Activity Anticancer

Activity Measurement 6.9

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay CCK-8 assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019